SBC Medical Group Holdings Incorporated (SBCWW) 株式分析

企業概要

SBC Medical Group Holdings Incorporated is an enterprise that delivers management services to cosmetic treatment centers operating across Japan, Vietnam, the United States, and Singapore. The firm operates within the healthcare sector, specifically focusing on the provision of advertising, marketing services via social media networks, as well as staff management solutions. This entity maintains a workforce comprising 863 employees, reflecting its operational scale in the international aesthetic medicine market. While specific sector and industry classifications are not disclosed in available data, the company's revenue of $173.61 million and a market capitalization that is not currently listed suggest it functions as a mid-to-small-cap entity within the global medical aesthetics industry. The absence of a reported market cap figure indicates that valuation multiples based on equity market size are either not applicable or not publicly tracked in standard databases for this specific ticker, which necessitates reliance on alternative metrics such as enterprise value or revenue multiples for analysis. The revenue figure of $173.61 million places the company in a significant position relative to smaller regional players, yet the lack of a listed market cap implies a trading structure that may involve over-the-counter markets or specific listing characteristics not captured in standard broad-market indices.

財務健全性

The company reported a trailing twelve-month revenue of $173.61 million, generating a net income of $50.99 million and an EBITDA of $70.17 million during the same period. The substantial gap between the revenue of $173.61 million and the net income of $50.99 million reveals a cost structure where operating expenses and taxes consume approximately 70.6% of total revenue, yet the high profitability suggests efficient cost management. The firm generated free cash flow of $25.41 million, which provides a clear indication of its financial flexibility to fund operations, repay debt, or pursue strategic acquisitions without relying solely on external financing. Profitability is further evidenced by a gross margin of 73.3%, an operating margin of 32.5%, and a profit margin of 29.4%, indicating that the company retains a significant portion of revenue after direct costs and operating expenses. Liquidity and leverage are managed with $164.09 million in cash holdings against $51.64 million in total debt, resulting in a debt-to-equity ratio of 19.61, which requires careful interpretation given the high leverage metric alongside strong cash reserves. The current ratio stands at 3.78, signaling robust short-term liquidity as the company holds nearly four times more current assets than current liabilities. Management effectiveness is highlighted by a return on equity of 22.3% and a return on assets of 13.0%, demonstrating that the company generates substantial returns relative to the capital invested by shareholders and the total asset base.

バリュエーション評価

Valuation metrics for SBC Medical Group Holdings Incorporated include a price-to-book ratio of 0.11, while trailing and forward P/E ratios are not available in the provided data. The price-to-book ratio of 0.11 indicates that the market values the company's equity at approximately 11% of its book value, suggesting a significant discount relative to the net asset value recorded on the balance sheet. Alternative valuation multiples such as the price-to-sales ratio and EV/EBITDA are not disclosed, limiting the ability to compare the firm against peers using standard earnings or sales-based multiples. The stock's price volatility is characterized by a 52-week high of $0.27 and a 52-week low of $0.26. Assuming the current trading price is near the low end of this range, the stock is trading approximately 0% to 3.7% below the 52-week high, reflecting a highly compressed trading range. The beta value of 0.99 indicates that the stock's price volatility tracks the broader market movements almost one-to-one, suggesting it does not exhibit excessive sensitivity to market fluctuations compared to the average stock.

Growth & Income

The company's financial trajectory is defined by a revenue growth rate of -10.9% year-over-year contrasted with an earnings growth rate of 117.5% year-over-year. This divergence indicates that earnings are growing significantly faster than revenue, likely driven by cost reductions, one-time gains, or margin expansion rather than top-line volume growth. As a non-dividend payer, the company does not distribute a dividend yield or maintain a payout ratio, implying that it retains earnings to reinvest into growth initiatives or bolster its cash reserves. The overall growth and income profile reveals a capital-light expansion strategy focused on profitability improvement despite a contraction in total sales. The absence of dividend payments combined with negative revenue growth but surging earnings suggests a distinct capital allocation philosophy where shareholder returns are prioritized through share price appreciation or balance sheet strengthening rather than cash distributions.